| Literature DB >> 29531851 |
Harini Kantamneni1, Margot Zevon2, Michael J Donzanti2, Xinyu Zhao3, Yang Sheng3, Shravani R Barkund2, Lucas H McCabe4, Whitney Banach-Petrosky5, Laura M Higgins2, Shridar Ganesan5, Richard E Riman6, Charles M Roth1,2, Mei-Chee Tan3, Mark C Pierce7, Vidya Ganapathy8, Prabhas V Moghe9,10.
Abstract
The identification and molecular profiling of early metastases remains a major challenge in cancer diagnostics and therapy. Most in vivo imaging methods fail to detect small cancerous lesions, a problem that is compounded by the distinct physical and biological barriers associated with different metastatic niches. Here, we show that intravenously injected rare-earth-doped albumin-encapsulated nanoparticles emitting short-wave infrared light (SWIR) can detect targeted metastatic lesions in vivo, allowing for the longitudinal tracking of multi-organ metastases. In a murine model of basal human breast cancer, the nanoprobes enabled whole-body SWIR detection of adrenal gland microlesions and bone lesions that were undetectable via contrast-enhanced magnetic resonance imaging (CE-MRI) as early as, respectively, three weeks and five weeks post-inoculation. Whole-body SWIR imaging of nanoprobes functionalized to differentially target distinct metastatic sites and administered to a biomimetic murine model of human breast cancer resolved multi-organ metastases that showed varied molecular profiles at the lungs, adrenal glands and bones. Real-time surveillance of lesions in multiple organs should facilitate pre-therapy and post-therapy monitoring in preclinical settings.Entities:
Keywords: cancer metastasis; nanotechnology; rare earths; shortwave infrared imaging
Year: 2017 PMID: 29531851 PMCID: PMC5844578 DOI: 10.1038/s41551-017-0167-9
Source DB: PubMed Journal: Nat Biomed Eng ISSN: 2157-846X Impact factor: 25.671